Colorectal cancer management: strategies in drug delivery

Singh, Prabha; Waghambare, Pramita; Khan, Tabassum; Omri, Abdelwahab

doi:10.1080/17425247.2022.2084531

Cited by 11 publications

(4 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, several studies have demonstrated that the synergistic activity of combined drugs was influenced by the ratio of drugs, doses, and administration schedule. [48][49][50] Encouraged by the selective antibacterial effect against Fn and effective inhibition toward the Fn-induced autophagy of 5-FU-LA@PPL, we determined the cytotoxicity of combined 5-FU and OxPt with a series of total drug concentrations and kept the ratio constant within the range of clinical usage for CRC cells via the MTT assay (Fig. 3c-e and Fig.…”

Section: In Vitro Synergistic Combination Chemotherapy Of 5-fu-la@pplmentioning

confidence: 99%

Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against Fn-associated colorectal tumor

Su,

Wen,

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: In Vitro Synergistic Combination Chemotherapy Of 5-fu-la@pplmentioning

confidence: 99%

Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against Fn-associated colorectal tumor

Su,

Wen,

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…They can also be used for delivering multiple drug simultaneously, for treating complex diseases. Since, microsponges adhere to the colorectal mucosa, providing prolonged residence and drug remains at the site for longer time [16,17] .…”

Section: Introductionmentioning

confidence: 99%

Advancements in microsponges for the management of vaginal and colorectal diseases: A comprehensive review

Rathi,

Kaur,

Chopra

et al. 2024

Appl. Chem. Eng.

View full text Add to dashboard Cite

The controlled-release drug delivery systems have risen dramatically allowing various factors such as the prohibitive cost of developing new entities, the expiration of existing international patents, and the discovery of new polymeric materials suitable for prolonged drug release and improvement in therapeutic efficacy. Microsponges are the porous microspheres-based polymeric delivery system that allows controlled drug release at a specific site. Microsponges are developed for the efficient delivery of active ingredients at a low dose. They help in improving stability by modifying drug release kinetics, reducing side effects, and enhancing the retention of drug entities. Microsponge compositions are stable throughout a wide pH and temperature range, making them more compatible with numerous vehicles, and ingredients. Several studies have shown that microsponges are non-irritant, non-toxic, non-mutagenic, and non-allergic with self-sterilizing properties. They are typically used for topical administration but have lately been used for oral, vaginal, and colorectal administration as well. The current review contains basic information about microsponges, their method of preparation, and various characterization parameters. The review also discusses the application of microsponges in vaginal and colorectal diseases. The latter portion of the script includes various patents and preclinical trials.

show abstract

“…In recent years, researchers have developed various chemotherapeutic drugs, such as doxorubicin, gemcitabine, oxaliplatin (Oxa), and so on, for cancer treatment. Among them, Oxa is one of the most commonly used chemotherapeutic drugs (Singh et al 2022 ). Currently, the combination chemotherapeutic regimen based on Oxa remains the first-line treatment for CRC, primarily including the FOLFOX regimen (Oxa + calcium folinate + fluorouracil) and the XELOX regimen (capecitabine + Oxa).…”

Section: Introductionmentioning

confidence: 99%

β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo

Deng,

Yan,

Gong

et al. 2024

Mol Med

View full text Add to dashboard Cite

Background Ketone β-hydroxybutyrate (BHB) has been reported to prevent tumor cell proliferation and improve drug resistance. However, the effectiveness of BHB in oxaliplatin (Oxa)-resistant colorectal cancer (CRC) and the underlying mechanism still require further proof. Methods CRC-Oxa-resistant strains were established by increasing concentrations of CRC cells to Oxa. CRC-Oxa cell proliferation, apoptosis, invasion, migration, and epithelial-mesenchymal transition (EMT) were checked following BHB intervention in vitro. The subcutaneous and metastasis models were established to assess the effects of BHB on the growth and metastasis of CRC-Oxa in vivo. Eight Oxa responders and seven nonresponders with CRC were enrolled in the study. Then, the serum BHB level and H3K79me, H3K27ac, H3K14ac, and H3K9me levels in tissues were detected. DOT1L (H3K79me methyltransferase) gene knockdown or GNE-049 (H3K27ac inhibitor) use was applied to analyze further whether BHB reversed CRC-Oxa resistance via H3K79 demethylation and/or H3K27 deacetylation in vivo and in vitro. Results Following BHB intervention based on Oxa, the proliferation, migration, invasion, and EMT of CRC-Oxa cells and the growth and metastasis of transplanted tumors in mice were suppressed. Clinical analysis revealed that the differential change in BHB level was associated with drug resistance and was decreased in drug-resistant patient serum. The H3K79me, H3K27ac, and H3K14ac expressions in CRC were negatively correlated with BHB. Furthermore, results indicated that H3K79me inhibition may lead to BHB target deletion, resulting in its inability to function. Conclusions β-hydroxybutyrate resensitized CRC cells to Oxa by suppressing H3K79 methylation in vitro and in vivo.

show abstract

Colorectal cancer management: strategies in drug delivery

Cited by 11 publications

References 121 publications

Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against Fn-associated colorectal tumor

Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against Fn-associated colorectal tumor

Advancements in microsponges for the management of vaginal and colorectal diseases: A comprehensive review

β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo

Contact Info

Product

Resources

About